Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
Director Thomas Haughey of ANI Pharmaceuticals Inc (NASDAQ:ANIP) sold 19,341 shares of common stock on August 12, 2025, according to a recent SEC filing. The transactions were executed at prices ranging from $84.50 to $87.16, with an average price of $85.93, netting Haughey approximately $1.66 million. The sale comes as the $1.81B market cap company’s stock trades near its 52-week high of $90.23, having surged 30% in the past week alone. Following the sale, Haughey directly owns 36,521 shares of ANI Pharmaceuticals. InvestingPro analysis indicates the stock is trading at Fair Value, with technical indicators suggesting overbought conditions. Subscribers can access 15 additional ProTips and comprehensive analysis in the Pro Research Report.
In other recent news, ANI Pharmaceuticals reported strong financial results for the second quarter of 2025, surpassing market expectations. The company achieved an adjusted earnings per share of $1.80, exceeding the FactSet consensus estimate of $1.41. Revenue also outperformed forecasts, reaching $211.4 million against an anticipated $187.34 million. This robust performance led ANI Pharmaceuticals to raise its guidance for revenue, adjusted EBITDA, and EPS. Following these developments, H.C. Wainwright increased its price target for ANI Pharmaceuticals to $93 from $84, maintaining a Buy rating. Similarly, Truist Securities raised its price target to $77 from $65, while keeping a Hold rating. The increased revenue from the Cortrophin Gel product, which grew 66% year-over-year, was a significant contributor to these positive results. These recent developments highlight the company’s strong position and growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.